Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efimosfermin in MASH with Compensated Cirrhosis
NCT06920043Phase 2Recruiting
- Sponsor
- GSK
- Start
- Apr 2025
- Primary completion
- Jul 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efimosfermin in metabolic dysfunction-associated steatohepatitis (MASH) and Cirrhosis (3 arms), sponsored by GSK. Primary endpoint: Number of participants with treatment emergent adverse events at 100 weeks. Started Apr 2025; status: recruiting.
02
Drugs
efimosfermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Cirrhosis
Beyond the preview
Go deeper on NCT06920043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06920043.